Small and Medium Enterprise
Creative Animodel posted this:Animal Model Products & ServicesAs a world leader in custom transgenic animal model, Creative Animodel has years of experience serving hundreds of clients across six continents. Our full-service model has enabled medical and academic researchers to receive over 1,000 successful and unique gene targeted animal model lines. Creative Animodel's clients return regularly for the experience, service and results that push research forward.
RAMOT at Tel Aviv University Ltd. posted this:Macrolid Induced Correction of Premature Stop Codons: A novel Treatment for Colorectal CancerAn antibiotic of the Macrolid family was demonstrated as a new treatment for colorectal cancer and other genetic human diseases that arise from pre-mature stop codons in important coding sequences. Project ID : 10-2007-109
RAMOT at Tel Aviv University Ltd. posted this:A New Application for Vitamin DCalcitriol (1,25-dihydroxyvitamin D3), the main hormonally active metabolite of vitamin D was found, in vitro, together with some of its synthetic analogs to have the potential to reduce the damage inflicted to normal tissue by accepted anti-cancer therapy. Project ID : 10-2007-101
RAMOT at Tel Aviv University Ltd. posted this:A novel approach for a genome-wide detection of synthetically-lethal genes in cancer: Towards rational drug target identification and personalized treatmentsSynthetic lethality occurs when a perturbation of two nonessential genes is lethal. This phenomenon offers a unique opportunity to develop selective anticancer drugs that will target a gene whose Synthetic Lethal (SL)-partner is inactive only in the cancer cells. Towards the realization of this potential, screening technologies have been developed to detect SL-interactions in model organisms and in human cell lines. However, currently their scope falls short compared to the large spectrum of interactions that need to be surveyed in cancer. Here we present a data-driven computational pipeline for the genome-wide identification of SL-interactions in cancer, by analyzing large volumes of genomic profiles of cancer cell lines and clinical samples. Our approach is first shown to successfully capture the SL-partners of tumor suppressors and oncogenes, according to six published experimental SL-screens. Second, we construct the first genome-wide network of SL-interactions in cancer and demonstrate its utility in predicting gene essentiality in a cancer-specific manner. Third, we show that, as predicted, underexpression of SL-partners has a strong positive prognostic value for cancer survival. Fourth, we identify synthetic lethality arising from gene over-activation and show that it can be utilized to predict anticancer drug efficacy. Lastly, we develop a complementary computational approach that by harnessing the obtained SL-networks identifies the most suitable treatment per patient, and identifies novel anticancer drug-targets, providing drug repurposing leads. Our approach provides a solid basis guiding future experimental studies aimed at developing new, selective anticancer therapies. Project ID : 2-2013-713
Ricardo Azuero posted this:
Research Assistant at Biomedicine and Biotechnology Center - Leipzig University
IDIBELL posted this:Companion diagnostic for cutaneous and uveal melanomaCompanion diagnostic for cutaneous and uveal melanoma. Our combination drug therapy for metastatic melanoma offers an alternative treatment for patients that do not have the BRAF V600 mutation or for patients resistant to Vemurafenib. Additionally, our technology can be used as a prognostic test to predict the risk of metastasis in uveal and cutaneous melanoma.
UACOOPERA University of Aveiro posted this:
Technology Transfer Office at uacoopera
Universidad de Alcalá-OTRI posted this:Nanoconjugates formed by dendritic molecules and peptides as antitumor agents against advanced prostate cancer.The Research Group in "Dendrimers for Biomedical Applications" of the University of Alcalá presents a new invention that refers to the formation of nanoconjugates with antitumor activity, mainly against advanced prostate cancer. Nanoconjugates are composed of dendritic systems (dendrimers and dendrons) and neuropeptides. The dendritic molecules are mainly of carbosilane structure and with ammonium functions in the periphery. And the peptides are preferably of the glucagon / secretin family (VIP, GHRH, PACAP…etc.) The research group seeks companies from the Biomedicine, Pharmaceutical and Health sector, to establish licensing agreements, cooperation agreements or commercial agreements with technical assistance.